Tr1诱导的免疫耐受在支气管哮喘中的研究进展  

Research progress of Tr1 induced immune tolerance in bronchial asthma

作　　者：孙菲 彭海英 蒋云秀 鲁德玕[2] Sun Fei;Peng Haiying;Jiang Yunxiu;Lu Degan(Graduate Department of Shandong First Medical University,Jinan 250000,China;Department of Respiratory and Critical Diseases,the First Affiliated Hospital of Shandong First Medical University(Qianfoshan Hospital of Shandong Province),Jinan 250014,China)

机构地区：[1]山东第一医科大学研究生处,济南250000 [2]山东第一医科大学第一附属医院(山东省千佛山医院)呼吸与危重症科,济南250014

出　　处：《国际免疫学杂志》2022年第1期96-101,共6页International Journal of Immunology

摘　　要：支气管哮喘是严重影响人类健康的以气道炎症、气道高反应性、气道重塑为特征的一种异质性疾病。目前支气管哮喘的发病机制仍不明确,机体对变应原的免疫耐受缺陷是导致哮喘发生的一个重要原因。1型调节性T细胞(type 1 T regulatory cells,Tr1)可以诱导免疫耐受,是过敏原特异性免疫疗法(allergen specific immunotherapy,AIT)的理论基础之一。促进Tr1细胞分化成功建立机体免疫耐受状态或许是支气管哮喘防治的关键。文章对支气管哮喘中Tr1细胞诱导免疫耐受的机制以及AIT的最新进展进行综述。Bronchial asthma is a heterogeneous disease characterized by airway inflammation,airway hyperresponsiveness and airway remodeling.At present,the pathogenesis of bronchial asthma is still unclear.The lack of immune tolerance to allergens is an important cause of asthma.Type 1 T regulatory cells(Tr1)can induce immune tolerance,which is one of the theoretical bases of allergen specific immunotherapy(AIT).Promoting Tr1 cell differentiation and successfully establishing immune tolerance may be the key to the prevention and treatment of bronchial asthma.This review summarized the mechanism of immune tolerance induced by Tr1 cells in bronchial asthma and the latest progress of AIT.

关 键 词：支气管哮喘 1型调节性T细胞 免疫耐受 过敏原特异性免疫疗法 

分 类 号：R562.25[医药卫生—呼吸系统]